These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28121547)

  • 21. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 22. How much will Herceptin really cost?
    Barrett A; Roques T; Small M; Smith RD
    BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trust's refusal to fund trastuzumab was "arbitrary".
    Dyer C
    BMJ; 2006 Apr; 332(7544):747. PubMed ID: 16575068
    [No Abstract]   [Full Text] [Related]  

  • 24. Managing oncology drug costs in a constrained environment.
    Clark P
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):90-93. PubMed ID: 30845110
    [No Abstract]   [Full Text] [Related]  

  • 25. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.
    Prasad V; Kaestner V
    Semin Oncol; 2017 Apr; 44(2):132-135. PubMed ID: 28923211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Dose reassessment: An answer to the high cost of drugs used in oncology?].
    Levêque D
    Bull Cancer; 2019 Sep; 106(9):719-724. PubMed ID: 31202558
    [No Abstract]   [Full Text] [Related]  

  • 27. American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs.
    American Society of Clinical Oncology
    J Oncol Pract; 2018 Mar; 14(3):187-192. PubMed ID: 29091534
    [No Abstract]   [Full Text] [Related]  

  • 28. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
    American Society of Clinical Oncology
    J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
    [No Abstract]   [Full Text] [Related]  

  • 29. Adjuvant trastuzumab for breast cancer: the other side of the coin.
    Gopalakrishnan S; Linnane J
    BMJ; 2005 Nov; 331(7526):1202-3. PubMed ID: 16293846
    [No Abstract]   [Full Text] [Related]  

  • 30. Seeking value as cancer drug costs soar.
    Bender E
    Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perspectives on Cost and Value in Cancer Care.
    Saltz LB
    JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
    [No Abstract]   [Full Text] [Related]  

  • 32. The shortage of essential chemotherapy drugs in the United States.
    Gatesman ML; Smith TJ
    N Engl J Med; 2011 Nov; 365(18):1653-5. PubMed ID: 22040130
    [No Abstract]   [Full Text] [Related]  

  • 33. [Patients with cancer denied treatment with new expensive drugs].
    Linné T
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1298. PubMed ID: 22852261
    [No Abstract]   [Full Text] [Related]  

  • 34. Novel approaches to delivering value in oncology drugs.
    Miller S
    Clin Adv Hematol Oncol; 2016 Apr; 14(4):244-6. PubMed ID: 27166606
    [No Abstract]   [Full Text] [Related]  

  • 35. Economic burden of cancer across the European Union: a population-based cost analysis.
    Luengo-Fernandez R; Leal J; Gray A; Sullivan R
    Lancet Oncol; 2013 Nov; 14(12):1165-74. PubMed ID: 24131614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Approvals in 2016: cost-benefit challenges of new anticancer agents.
    Savage P
    Nat Rev Clin Oncol; 2017 Feb; 14(3):133-134. PubMed ID: 28218257
    [No Abstract]   [Full Text] [Related]  

  • 37. United healthcare, five oncology practices try bundled payments.
    Goozner M
    J Natl Cancer Inst; 2011 Jan; 103(1):8-10. PubMed ID: 21169535
    [No Abstract]   [Full Text] [Related]  

  • 38. Minimalism in oncology.
    The Lancet Oncology
    Lancet Oncol; 2018 May; 19(5):579. PubMed ID: 29726372
    [No Abstract]   [Full Text] [Related]  

  • 39. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
    Hillner BE; Smith TJ
    J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
    [No Abstract]   [Full Text] [Related]  

  • 40. Value in Oncology: It Is in the Eyes of the Beholder.
    Nabhan C; Phillips EG; Feinberg BA
    J Natl Compr Canc Netw; 2019 Jan; 17(1):2-5. PubMed ID: 30659123
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.